Short Interest in Talphera, Inc. (NASDAQ:TLPH) Drops By 15.4%

Talphera, Inc. (NASDAQ:TLPH) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 75,400 shares, a decline of 15.4% from the January 31st total of 89,100 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily trading volume, of 94,800 shares, the short-interest ratio is currently 0.8 days.

Talphera Price Performance

Shares of TLPH opened at $0.54 on Wednesday. The firm has a 50-day simple moving average of $0.61 and a two-hundred day simple moving average of $0.76. Talphera has a 1-year low of $0.50 and a 1-year high of $1.32. The stock has a market cap of $9.11 million, a PE ratio of -0.78 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TLPH shares. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Talphera in a research report on Tuesday, January 21st. Finally, Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. purchased a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera comprises about 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest position. Rosalind Advisors Inc. owned 4.47% of Talphera as of its most recent SEC filing. 37.67% of the stock is owned by institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.